Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
A8K7I4

UPID:
CLCA1_HUMAN

ALTERNATIVE NAMES:
Calcium-activated chloride channel family member 1; Calcium-activated chloride channel protein 1

ALTERNATIVE UPACC:
A8K7I4; B2RAV5; O95151; Q5TDF4; Q9UNF6; Q9UPC6

BACKGROUND:
The protein Calcium-activated chloride channel regulator 1, alternatively named Calcium-activated chloride channel protein 1, is implicated in calcium-activated chloride conductance. It has critical roles in mucus hypersecretion, cystic fibrosis, and airway hyper-responsiveness (AHR), besides influencing goblet cell metaplasia and innate immune response inflammation. It also induces MUC5AC, suggesting a role in tumor suppression.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Calcium-activated chloride channel regulator 1 offers promising avenues for therapeutic intervention, especially in managing diseases like cystic fibrosis and in strategies aimed at mucus regulation and inflammation control.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.